Qvin

Qvin is a San Francisco-based diagnostics company founded in 2018 that is commercializing a novel diagnostic platform centered on menstrual blood. The company's core innovation is the FDA-cleared Q-Pad, a collection device that enables the measurement of validated biomarkers (e.g., HbA1c, TSH, AMH) from menstrual effluent, correlating strongly with venous blood. By transforming a routine biological process into a diagnostic tool, Qvin seeks to revolutionize women's health research, improve early disease detection for conditions like diabetes and endometriosis, and create a more patient-centric, accessible testing paradigm. The company operates as a private, likely pre-revenue entity focused on research collaborations and future product commercialization.

Proprietary diagnostic platform utilizing the Q-Pad, an FDA-cleared menstrual pad with an embedded collection strip, to enable non-invasive, at-home collection of menstrual blood for biomarker analysis. The platform is validated to measure systemic biomarkers (e.g., HbA1c, TSH) and research gynecologic-specific biomarkers from menstrual effluent.

Qvin is a first-mover in the specific niche of FDA-cleared menstrual blood diagnostics. Broader competition includes central lab services (Quest, LabCorp) using traditional blood draws, other FemTech diagnostic companies (e.g., Everlywell, Modern Fertility) using finger-prick blood or saliva, and research-stage efforts exploring other non-invasive biomarkers. Qvin's unique IP around collection and validation for menstrual blood is its primary differentiator.